Newer Agents in Heart Failure Management
Start with the big picture
The lesson surveys contemporary agents and their roles in heart failure management. It covers sacubitril/valsartan, which combines neprilysin inhibition with AT₁ receptor blockade, and ivabradine, which lowers heart rate through funny-current inhibition. SGLT2 inhibitors are discussed for benefits in HFrEF and HFpEF, while vericiguat and omecamtiv mecarbil illustrate other approaches for selected HFrEF populations. The topic also introduces finerenone, investigational lipid-targeting therapy, partial A₁ agonists, soluble neprilysin agonists and serelaxin. Intravenous ferric carboxymaltose is included as a therapy for iron deficiency in heart failure. Across these agents, the lesson connects mechanisms with reported clinical outcomes and clarifies where evidence or development remains uncertain.
What you'll learn
- Describe how sacubitril/valsartan combines neprilysin inhibition and AT₁ receptor blockade.
- Explain the heart-rate effect and clinical role of ivabradine.
- Summarize the roles of SGLT2 inhibitors, vericiguat, and omecamtiv mecarbil in heart failure.
- Distinguish established therapies from agents with investigational or uncertain status.
- Identify the place of intravenous ferric carboxymaltose in iron-deficient heart failure.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
